[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital Freiburg\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":439},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,42,71,102,124,152,183,207,241,271,295,326,346,372,392,415],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100558292","genetic-newborn-screening-for-rare-diseases-within-the-screen4care-project-100558292",false,"NCT06549218","Genetic Newborn Screening for Rare Diseases Within the Screen4Care Project","Shortening the Path to Rare Disease Diagnosis by Using Newborn Genetic Screening and Digital Technologies (SCREEN4CARE): Genetic Newborn Screening for Rare Diseases Within the Screen4Care Project","SCREEN4CARE","Inclusion Criteria:\n\n* TREAT-panel:\n\n  * newborns\n  * Infants born in one of the participating hospitals and birth centres\n  * Informed consent signed by both parents\u002Flegal guardian to participate in genetic newborn screening (TREAT-panel)\n* Whole genome sequencing:\n\n  * Participation in the TREAT-panel study\n  * Symptoms suggestive of a genetic disease within the first 2 years of life\n  * Informed consent signed by both parents\u002Flegal guardian to participate in genetic newborn screening (TREAT-panel) and the whole genome sequencing\n\nExclusion Criteria:\n\n* Missing informed consent of parents\u002Flegal guardian",true,"ALL","2 Years",{"count":21,"type":22},20000,"ESTIMATED","INTERVENTIONAL",[25],"NA","The main objective of the genetic newborn screening part of the Screen4Care-project is to shorten the path to rare disease diagnosis and to facilitate early intervention. Therefore, genetic newborn screening for currently treatable rare diseases (TREAT-panel approach) will be offered to families expecting a baby. Whole genome sequencing (WGS) will be offered as additional diagnostic approach to newborns participating in Screen4Care TREAT-panel approach, if they develop symptoms suggestive of a genetic disease.\n\nTo evaluate to what extend genetic newborn screening has an impact on participating infants and their families, a follow-up with standardised questionnaires will be performed for all participating families.",[28],"Newborn Screening","RECRUITING","2026-04-28",{"date":32,"type":33},"2026-05-04","ACTUAL",{"date":35,"type":33},"2024-12-03",{"date":37,"type":22},"2026-12",{"name":39,"class":40},"University Hospital Freiburg","OTHER",8,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100107393","study-for-epidemiology-and-characterization-of-myelodysplastic-syndromes-mds-and-juvenile-myelomonocytic-leucemia-jmml-in-childhood-100107393","NCT00662090","Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood","Prospective Non-randomized Multi-center Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood","EWOG MDS 2006","Inclusion Criteria:\n\n* Written informed consent by the caretakers and whenever possible the patient's assent.\n* Confirmed diagnosis of MDS or JMML (morphology, cytogenetics)\n* Myeloid leukemia of Down syndrome (patients aged \\> 6 years).\n* Age less than 18 years\n\nExclusion Criteria:\n\n* Denied informed consent and\u002For assent by caretakers\u002Fpatient.\n* Myeloid leukemia of Down syndrome (patients \\\u003C 6 years).\n* Participation in another study within the last 4 weeks (except for therapy optimizing studies in cancer or bone marrow failure disorders and studies in diagnostics).","17 Years",{"count":52,"type":22},260,"OBSERVATIONAL","The aim of the study is to improve the accuracy of diagnosis for children and adolescents with MDS by a standardized review of morphology and standardized cytogenetic and molecular analysis.\n\nThe primary objectives of the study are:\n\n* To evaluate the frequency of the different subtypes of MDS in childhood and adolescence by a standardized diagnostic approach\n* To evaluate the frequency of cytogenetic and molecular abnormalities:\n\nSpecifically using array-CGH to evaluate the frequency of subtle chromosomal imbalances, i.e. gains and losses of defined chromosomal regions, and amplifications.\n\nSpecifically using mFISH to identify unknown chromosomal aberrations, particularly subtle translocations involving new candidate genes, and to better define chromosomal breakpoints.\n\nThe secondary objectives of the study are:\n\n* To assess survival for children and adolescents with MDS and JMML\n* To evaluate relapse rate, morbidity and mortality in children with MDS and JMML treated by HSCT",[56,57],"Myelodysplastic Syndromes","Juvenile Myelomonocytic Leukemia",[59,60,61,62,63],"MDS","JMML","EWOG-MDS","Myelodysplastic Syndromes (MDS)","Juvenile Myelomonocytic Leukemia (JMML)",{"date":32,"type":33},{"date":66,"type":33},"2010-04",{"date":68,"type":22},"2027-12",{"name":39,"class":40},1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":18,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":70},"100560422","early-tips-in-patients-with-liver-cirrhosis-and-ascites-100560422","NCT06576934","Early TIPS in Patients With Liver Cirrhosis and Ascites","Early Implantation of a Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Patients With Liver Cirrhosis and Ascites: a Multicentre, Randomised Controlled Trial","eTIPS","Inclusion Criteria:\n\nPatients eligible for inclusion in this trial must meet all of the following criteria:\n\n1. Patients ≥ 18 years and \\\u003C 80 years\n2. Liver cirrhosis as documented by previous liver biopsy or by a combination of typical clinical, biochemical and sonographic features\n3. Ascites as the first single decompensating event with grade 2 ascites and MELD ≥ 15 OR grade 3 ascites\n4. INR ≤ 1.5\n5. Ability to understand the nature of the trial and the trial related procedures and to comply with them\n\nExclusion Criteria:\n\nPatients eligible for this trial must not meet any of the following criteria:\n\n1. Treatment refractory or recurrent ascites at the time of study inclusion\n2. Patients with concomitant variceal bleeding fulfilling the criteria for pre-emptive TIPS implantation (Child-Pugh class C \\\u003C 14 points or Child-Pugh class B \\>7 with active bleeding at initial endoscopy or hepatic venous pressure gradient \\[HVPG\\] \\> 20 mmHg at the time of bleeding)\n3. Budd-Chiari syndrome\n4. Portal vein thrombosis (PVT)\n5. Spontaneous bacterial peritonitis (SBP)\n6. Uncontrolled systemic infection (defined as an increase of \\> 20% if inflammatory parameters \\[C-reactive protein, procalcitonin, leukocytes\\] and\u002For sepsis as a reason for development of ascites\n7. Cardiac cirrhosis (defined as the development of liver cirrhosis in a patient with cardiac heart failure due to primary cardiac disease)\n8. Clinical significant cardiac disease (NYHA ≥II)\n9. Untreated valvular heart disease: middle to high-grade valve stenosis or insufficiency (applies to mitral, tricuspid, aortic and pulmonary valves)\n10. Diastolic dysfunction grade III, stated by transthoracic echocardiogram (TTE)\n11. Reduced left ventricular ejection fraction ≤50%\n12. Pulmonary hypertension (mean pulmonary arterial pressure \\> 45 mmHg)\n13. Bilirubin \\> 3 mg\u002Fdl\n14. Obstructive cholestasis\n15. Hepatorenal syndrome type AKI (HRS-AKI)\n16. Acute on chronic liver failure\n17. Benign liver tumor within the potential puncture tract\n18. Patient after liver transplantation\n19. Prior TIPS implantation\n20. Ongoing and\u002For recurrent hepatic encephalopathy (grade \\>II)\n21. Active tumor disease including hepatocellular carcinoma defined as need for chemotherapy, radiation therapy, interventional or surgical treatment\n22. New onset of antiviral treatment for chronic hepatitis B virus (HBV) infection within the last 3 months\n23. Untreated chronic hepatitis C virus (HCV) infection\n24. Life expectancy \\\u003C1 year\n25. Pregnant or breastfeeding women\n26. Patients without the legal capacity who are unable to understand the nature, significance and consequences of the study\n27. Simultaneous participation in other interventional trials which could interfere with this trial; simultaneous participation in registry and diagnostic trials is allowed\n28. Person who is in a relationship of dependence\u002Femployment with the sponsor or the investigator","18 Years","80 Years",{"count":82,"type":22},134,[25],"The aim of this clinical trial is to compare the safety and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) implantation with standard treatment (diuretic medications, and if necessary, paracenteses) in patients with liver cirrhosis and development of ascites as the first decompensating event.\n\nBy creating a shunt between the liver vein and the portal vein, blood is diverted from the portal vein directly into the hepatic vein, which results in a reduction of pressure in the portal vein so that development of ascites is reduced.",[86,87,88],"Liver Cirrhosis","Ascites Hepatic","Portal Hypertension",[90,91,92,93],"liver cirrhosis","Transjugular intrahepatic portosystemic shunt","ascites","MELD","2026-04-27",{"date":96,"type":33},"2026-05-01",{"date":98,"type":33},"2025-04-01",{"date":100,"type":22},"2029-02-15",{"name":39,"class":40},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":17,"sex":18,"minAge":79,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":118,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":70},"100512193","video-capsule-endoscopy-for-detection-of-gastrointestinal-bleeding-in-the-small-bowel-100512193","NCT05949268","Video Capsule Endoscopy for Detection of Gastrointestinal Bleeding in the Small Bowel","Video Capsule Endoscopy for Detection of Gastrointestinal Bleeding in the Jejunum","Inclusion Criteria:\n\n* suspicion of gastrointestinal bleeding in the small bowel undetected by gastroscopy and colonoscopy\n* informed consent\n\nExclusion Criteria:\n\n* contraindications for small bowel capsule endoscopy (e.g. stenosis)",{"count":110,"type":22},1300,"Small bowel capsule endoscopy is the main diagnostic standard for small bowel bleeding. This study investigates the detection rate of small bowel bleeding in capsule endoscopy and further endoscopic treatment in a prospective and retrospective cohort.",[113],"GastroIntestinal Bleeding",[115,116,117],"Small bowel capsule endoscopy","gastrointestinal bleeding","anticaogulation",{"date":96,"type":33},{"date":120,"type":33},"2023-09-01",{"date":122,"type":22},"2028-07-15",{"name":39,"class":40},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":18,"minAge":79,"maxAge":132,"enrollmentInfo":133,"targetDuration":135,"studyType":53,"phases":4,"briefSummary":136,"conditions":137,"keywords":142,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":70},"100499384","freiburg-tips-registry-100499384","NCT05782556","Freiburg TIPS Registry","Transjugular Intrahepatic Portosystemic Shunt (TIPS) for the Treatment of Portal Hypertension: an Observational Study","FRETIR","Inclusion Criteria:\n\n* Patients allocated to TIPS implantation due to clinically significant cirrhotic and non-cirrhotic portal hypertension\n\nExclusion Criteria:\n\n* Withdrawal of written informed consent","100 Years",{"count":134,"type":22},2000,"12 Months","Patients with clinically significant portal hypertension allocated to implantation of a transjugular intrahepatic portosystemic shunt (TIPS) at the Department of Medicine II of the University Medical Center Freiburg, Germany will be offered to participate in this prospective observational trial.\n\nClinical and laboratory as well as outcome parameters will be assessed before and within the first 12 months after TIPS implantation following a regular follow-up schedule with clinical visits at the University Medical Center Freiburg. During follow-up visits, serum\u002Fplasma samples and peripheral blood mononuclear cells (PBMC) are collected and stored in a associated biobank.",[86,88,138,139,140,141],"Non-Cirrhotic Portal Hypertension","Budd Chiari Syndrome","Portal Vein Thrombosis","Portal Systemic Shunt",[143,91,138,144,145],"Liver cirhosis","Prognosis","Outcome",{"date":96,"type":33},{"date":148,"type":33},"2023-01-01",{"date":150,"type":22},"2034-06-30",{"name":39,"class":40},{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":18,"minAge":79,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":161,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":174,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":70},"100620568","incidence-of-colon-ischemia-in-patients-after-cardiopulmonary-resuscitation-cpr-100620568","NCT07359313","Incidence of Colon Ischemia in Patients After Cardiopulmonary Resuscitation (CPR)","Incidence of Colon Ischemia in Patients After Cardiopulmonary Resuscitation (CPR): a Prospective Single-center Epidemiological Incidence Study","Inclusion Criteria:\n\n* adult patients (≥ 18 years) admitted to the participating department AND\n* in-hospital or out-of-hospital cardiac arrest (IHCA, OHCA)\n\nExclusion Criteria:\n\n* resuscitation period of ≤ 5 minutes\n* awake and contactable patients (GCS ≥ 13)",{"count":160,"type":22},200,[25],"Bedside colonoscopy 24-36 hours after successful CPR",[164],"Cardiac Arrest (CA)",[166,167,168,169,170,171,172,173],"cardiac arrest","cardiopulmonary resuscitation","CPR","extracorporeal cardiopulmonary resuscitation","ECPR","VA ECMO","colonoscopy","mesenteric ischemia","NOT_YET_RECRUITING","2026-01-13",{"date":177,"type":33},"2026-01-22",{"date":179,"type":22},"2026-01-07",{"date":181,"type":22},"2028-02-06",{"name":39,"class":40},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":18,"minAge":79,"maxAge":4,"enrollmentInfo":190,"targetDuration":192,"studyType":53,"phases":4,"briefSummary":193,"conditions":194,"keywords":196,"overallStatus":174,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":70},"100599271","european-prospective-bloodstream-infection-cohort-100599271","NCT07082322","European Prospective Bloodstream Infection Cohort","EPIC-BSI","Inclusion Criteria:\n\n* EPIC-BSI Registry: Positive blood cultures result. For each patient only the first positive blood culture result during 90 days would be counted.\n* EPIC-BSI Diagnostic study: Centre recruiting for the EPIC study with access to microbiological and clinical data.\n* EPIC-BSI Management study - Regular dataset: First two BSI cases per month of (at least two or three) target pathogens (S. aureus, E. faecalis\u002FE. faecium, E. coli, Klebsiella spp., P. aeruginosa, A. baumanii, Streptococcus spp.)\n\nExclusion Criteria:\n\n* EPIC-BSI Registry: Non-comprehensive documentation and reporting of BSI cases, Age \\\u003C 18 years\n* EPIC-BSI Diagnostic Study: EPIC BSI centre does not participate in the EPIC BSI Diagnostic Study arm\n* EPIC-BSI Management Study: Non-comprehensive documentation and reporting of BSI cases; Age \\\u003C 18 years; For Follow-up part: Patient with dementia or other progressed neurological or vigilance disorder without contact details of legal representative, which makes follow-up unfeasible",{"count":191,"type":22},40000,"90 Days","Background:\n\nBloodstream infections (BSIs) and sepsis continue to pose significant public health challenges, contributing to high morbidity and mortality worldwide. According to the Global Burden of Diseases Study, BSIs and sepsis are associated with approximately 20% of global deaths. However, the clinical characteristics of BSIs have evolved over recent years, showing significant variability across different countries and continents. The diversity in management standards across regions further complicates the generalization and transferability of research findings. Despite the critical need for comprehensive data, BSI research in Europe remains fragmented, often limited to national-level studies.\n\nProject Aim:\n\nThe EPIC-BSI project aims to address these challenges by establishing a multinational, collaborative bloodstream infection cohort across Europe and globally. The primary objectives are to:\n\n* Integrate national BSI research into a cohesive multinational cohort that enable large-scale comparative research by standardizing BSI incidence data, diagnostic and therapeutic approaches, and patient outcomes across European countries and beyond.\n* Monitor shifts in BSI characteristics, including the emergence of multi-drug resistant organisms, and changes in risk groups, diagnostics, and therapies.\n* Create a foundation for future studies and collaborations, such as integrating BSI data with international antibiotic usage, population data, health policy data, or by biobanking blood-borne pathogens for sequencing.\n\nThe study is divided into three arms focusing on BSI epidemiology (EPIC-BSI registry), diagnostics (EPIC-BSI Diagnostic Study) and management (EPIC-BSI Management study). The EPIC-BSI Management study is partitioned in different levels of data contribution to reduce barriers for centres and enable broad participation.\n\nSpecific Objectives and Endpoints:\n\nEPIC-BSI Registry:\n\n* Primary aim\u002Fendpoint: Establish an international prospective BSI cohort with anonymized inclusion of all BSI cases from participating centres allowing estimation of BSI incidence by pathogen in the participating centres.\n* Secondary aims\u002Fendpoints:\n\n  * Analyse the incidence of BSIs across different settings and countries.\n  * Monitor changes in patient demographics (age, gender) and acquisition modes.\n  * Track shifts in antimicrobial resistance patterns.\n  * Review effects of infection control practices on MDRO-BSI frequency\n\nEPIC-BSI Diagnostic Study:\n\n* Primary aim\u002Fendpoint: Biannual evaluation of diagnostic procedures and standards regarding BSI at participating centres\n* Secondary aims\u002Fendpoints:\n\n  * Assess the availability and use of (new) clinical and microbiological diagnostics.\n  * Identify gaps in diagnostic practices and time lags between scientific evidence, guideline publication and clinical implementation of new diagnostic utilities.\n\nEPIC-BSI Management Study:\n\n* Primary aim\u002Fendpoint: Analyse clinical data from BSI cases to evaluate management practices regarding the effect on in-hospital mortality and outcome on day 90 after onset incl. patient-reported outcomes (Desirability-of-outcome-ranking (DOOR) or health-related quality of life metrics)\n* Secondary aims\u002Fendpoints:\n\n  * Identify differences in clinical management across countries and hospital types.\n  * Analyse the impact of antimicrobial resistance patterns on clinical outcomes.\n  * Evaluate the effectiveness of different established therapeutic regimens.",[195],"Bloodstream Infection",[197,198],"Registry","Therapeutical management","2025-07-15",{"date":201,"type":33},"2025-07-24",{"date":203,"type":22},"2025-09-01",{"date":205,"type":22},"2031-01-01",{"name":39,"class":40},{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":18,"minAge":214,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":217,"conditions":218,"keywords":224,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":240},"100465202","special-care-patterns-for-elderly-hnscc-patients-undergoing-radiotherapy-100465202","NCT05337631","Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy","SENIOR","Inclusion Criteria:\n\n* definitive (chemo-)radiotherapy of locoregionally advanced (cT3-4 and\u002For cN+) head-and-neck squamous cell carcinomas (HNSCC) of the oral cavity, oropharynx, hypopharynx or larynx\n* primary treatment since 2005\n* age ≥65 years at the time of (chemo-)radiotherapy\n\nExclusion Criteria:\n\n* adjuvant (chemo-)radiotherapy\n* history of previous head-and-neck cancers or radiotherapy in the head-and-neck region\n* distant metastases at (chemo-)radiotherapy initiation (cM1)\n* HNSCCs of the nasopharynx, salivary glands, skin or with unknown primary","65 Years",{"count":216,"type":22},1500,"The number of elderly head-and-neck squamous cell carcinoma (HNSCC) patients is increasing; however, the evidence regarding the ideal treatment for this often vulnerable and frail patient cohort is limited. Although the benefit of concomitant chemotherapy has been reported to decrease in elderly HNSCC patients based on the MACH-NC meta-analysis, it remains unknown whether state-of-the art radiotherapy techniques such as intensity-modulated radiotherapy (IMRT), modern supportive treatments and alternative chemotherapy fractionation (e.g., cisplatin weekly) may have altered this observation. The objective of this retrospective multinational multicenter study is to determine the oncological outcomes of elderly patients (≥65 years) with locally advanced HNSCCs undergoing definitive (chemo-)radiation and to investigate the influence of concomitant chemotherapy on overall survival and progression-free survival after adjusting for potential confounder variables such as age, performance status and comorbidity burden.",[219,220,221,222,223],"HNSCC","Oral Cavity Cancer","Oropharynx Cancer","Hypopharynx Cancer","Larynx Cancer",[225,226,227,228,229,230,231],"Elderly","Radiotherapy","Chemotherapy","Chemoradiotherapy","Cisplatin","Cetuximab","Real-world data","2025-03-24",{"date":234,"type":33},"2025-03-25",{"date":236,"type":33},"2021-06-01",{"date":238,"type":22},"2026-12-31",{"name":39,"class":40},18,{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":18,"minAge":214,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":23,"phases":251,"briefSummary":253,"conditions":254,"keywords":256,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":270},"100579909","phase-3-adjusted-high-dose-chemotherapy-with-autologous-stem-cell-transplant-vs-conventional-immunochemotherapy-in-elderly-pcnsl-patients-100579909","NCT06830421","Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients","Age-adjusted High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation or Conventional Chemotherapy With R-MP as First-line Treatment in Elderly Primary CNS Lymphoma Patients - a Randomized Phase III Trial","PRIMA-CNS","Inclusion Criteria:\n\n1. Immunocompetent patients with newly-diagnosed primary DLBCL of the central nervous system.\n2. Age \\> 70 years or age 65-70 years if not eligible for more intensive treatment (e.g. OptiMATe trial).\n3. Histologically or cytologically assessed diagnosis of B-cell lymphoma by local pathologist.\n4. Diagnostic sample obtained by stereotactic or surgical biopsy, cerebrospinal fluid (CSF) cytology examination or vitrectomy.\n5. Disease exclusively located in the CNS.\n6. At least 1 measurable lesion.\n7. Eastern Cooperative Oncology Group (ECOG)-Performance Status (PS) ≤ 2. ECOG PS \\> 2 accepted if due to PCNSL symptoms.\n8. Patients possibly eligible for HCT-ASCT as judged by the treating physician.\n9. Written informed consent obtained according to international guidelines and local laws by patient or authorized legal representative in case patient is temporarily legally not competent due to his or her disease.\n\nAdditional randomization criteria:\n\n1. Patients eligible for HCT-ASCT defined by the EBL score (at most one of the 3 following conditions may apply: ECOG PS \\> 1, Barthel Index of activities of daily living (ADL) \\\u003C 20 and Lachs geriatric screening \\> 3), improvement of PS after pre-phase treatment or clinical judgement by the treating physician after discussion with the study expert team.\n2. No evidence of disease progression after pre-phase treatment.\n\nExclusion Criteria:\n\n1. Congenital or acquired immunodeficiency including HIV infection and previous organ transplantation.\n2. Systemic lymphoma manifestation (outside the CNS).\n3. Primary vitreoretinal lymphoma or primary leptomeningeal lymphoma without manifestation in the brain parenchyma or spinal cord.\n4. Previous or concurrent malignancies with the exception of surgically cured carcinoma in situ or other kinds of cancer without evidence of disease for at least 5 years.\n5. Previous systemic Non-Hodgkin lymphoma at any time.\n6. Inadequate renal function (creatinine clearance \\\u003C60 ml\u002Fmin).\n7. Inadequate bone marrow, cardiac, pulmonary or hepatic function according to investigator´s decision.\n8. Active hepatitis B or C disease.\n9. Concurrent treatment with other experimental drugs or participation in an interventional clinical trial with administration of study medication within the last thirty days before the start of this study.\n10. Third space fluid accumulation \\>500 ml.\n11. Hypersensitivity to study treatment or any component of the formulation.\n12. Taking any medications likely to cause interactions with the study medication.\n13. Known or persistent abuse of medication, drugs or alcohol.\n14. Active COVID-19-infection or non-compliance with the prevailing hygiene measures regarding the COVID-19 pandemic.\n15. Patients without legal capacity and who are unable to understand the nature, significance and consequences of the study and without designated legal representative.\n16. Previous participation in this trial.\n17. Persons who are in a relationship of dependency\u002Femployment to the sponsor and\u002F or investigator.\n18. Any familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.\n19. Fertile patients refusing to use safe contraceptive methods during the study.",{"count":250,"type":22},340,[252],"PHASE3","Most patients being diagnosed with primary diffuse large B-cell lymphoma of the central nervous system (PCNSL) are 60 years or older. Elderly patients with PCNSL have a poor prognosis and there is a great medical need to improve outcome for this vulnerable population. In Germany and many international centres, there are currently two widely used strategies to treat elderly PCNSL patients who are eligible for high-dose methotrexate (HD-MTX) treatment, which have not yet been compared head-to-head. The R-MP regimen has been established by the Cooperative PCNSL Study Group as a \"conventional\" immunochemotherapy standard treatment for elderly patients with newly diagnosed disease and consists of Rituximab, HD-MTX and Procarbazine followed by maintenance therapy with Procarbazine. In contrast, another recently established protocol also includes HD-MTX-based induction therapy, but followed by consolidating high-dose chemotherapy and autologous stem cell transplantation (HCT-ASCT). This is an overall more intensive, but substantially shorter treatment approach, feasible for elderly patients being considered eligible for a more intensive treatment. The PRIMA-CNS trial aims to compare these two treatment approaches with respect to survival, response rates and toxicity.",[255],"Primary Central Nervous System Lymphoma",[257,258,259,260,261],"Primary central nervous system lymphoma","HD-chemotherapy followed by autologous stem cell transplantation","Age-adjusted HCT-ASCT","First-line treatment in elderly PCNSL patients","HD-MTX induction","2025-02-11",{"date":264,"type":33},"2025-02-17",{"date":266,"type":33},"2023-08-09",{"date":268,"type":22},"2031-08-31",{"name":39,"class":40},35,{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":17,"sex":18,"minAge":79,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":281,"conditions":282,"keywords":284,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":70},"100448559","pathogen-microbiome-interaction-during-helicobacter-pylori-infection-100448559","NCT05121025","Pathogen-microbiome Interaction During Helicobacter Pylori Infection","Pathogen-microbiome Interaction in Human Response and Disease-outcome During Infection and Colonization With Helicobacter Pylori","PREDICTHP","Inclusion Criteria:\n\nPatients: -\n\n* Male and female patients aged ≥ 18 years.\n* Specimens from patients undergoing tissue sampling, stool, and blood to rule out Helicobacter pylori infection\n* Written informed consent from patients.\n\nVolunteer subjects: -\n\n* Male and female (non-pregnant) volunteers between the ages of 18-65 years.\n* Written informed consent from volunteers.\n* No acute medical conditions\n* No regular medication use, and no antibiotic use in the last 4 weeks.\n\nExclusion Criteria:\n\nPatients: -\n\n* Minor patients\n* Patients not capable of giving consent\n* Samples without sufficient residual material after standard diagnostic procedures\n* Samples from patients who have not given consent for testing\n\nVolunteer subjects: -\n\n* Subjects not capable of giving consent\n* Subjects with acute illnesses\n* Subjects older than 65 or younger than 18 years of age.\n* Pregnant women",{"count":280,"type":22},180,"Helicobacter pylori affects the gut microbiome in ways that are only partially understood. In which patients H. pylori causes severe disease and in whom it merely colonizes, possibly even with beneficial effects, is not understood. The investigators are pursuing the hypothesis that changes in the gut microbiome that can be easily measured in stool have such predictive value.",[283],"Helicobacter Pylori Infection",[285,286],"Helicobacter Pylori","Metagenomics","2024-12-04",{"date":289,"type":33},"2024-12-05",{"date":291,"type":33},"2022-03-11",{"date":293,"type":22},"2025-12-30",{"name":39,"class":40},{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":302,"targetDuration":303,"studyType":53,"phases":4,"briefSummary":304,"conditions":305,"keywords":307,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":70},"100570783","the-freiburg-registry-on-spontaneous-intercranial-hypotension-sih--post-dural-puncture-headache-pdph-100570783","NCT06711731","The Freiburg Registry on SpontanEous IntercrAnial Hypotension (SIH) & Post-duraL Puncture Headache (PDPH)","SEAL","Inclusion Criteria:\n\n1. Patients with suspected spinal CSF leak based on one of the following\n\n   * History of new orthostatic symptomes with or without prior spinal procedure\n   * Imaging suggestive for spinal CSF leak\n2. Informed consent\n\nExclusion Criteria:\n\na) Symptoms beeing conclusively explained by another known diagnosis",{"count":134,"type":22},"24 Months","Spinal CSF leaks are considered as rare disease. They cause a variety of symptoms, mainly culminating in a chronic headache syndrome. Crucially, yet often disregarded, the disease holds the potential for cure. The multitude of symptoms, and their inconsistency over time are just two of many challenges preventing timely diagnosis and treatment in many patients.\n\nSpinal CSF leaks can occur after intentional or accidental dural puncture (post-dural puncture headache - PDPH) or spontaneously (spontaneous intracranial hypotension - SIH). Awareness is steadily increasing with simultaneous increase of recognized patients. Yet, research and diagnostic is mainly provided by few specialized centers, as e.g. Freiburg. Thus, many observations point towards a large non-diagnosed and non-recognized number of patients, most likely being misdiagnosed and mistreated.\n\nObjective: The aim of the registry is to collect structured information on the frequency, cause, symptoms, diagnostic procedures, treatment options and long-term outcome. With the help of the registry, we would like to contribute to a better understanding and treatment of the diseases.\n\nMethods: Prospective, longitudinal registry on patients with suspected SIH or PDPH, including data on demographics, clinical presentation, diagnostic findings, treatment, at treatment outcome.",[306],"CerebroSpinal Fluid (CSF) Leak",[308,309,310,311,312,313,314,315,316,317],"SIH","PDPH","Spinal leaks","CSF leak","SLEC","Spontaneouse Intercranial Hypotension","CSF-venous fistula","Post Dural Puncture Headache","Cerebrospinal Fluid Leak","Rare disease","2024-11-26",{"date":320,"type":33},"2024-12-02",{"date":322,"type":33},"2024-11-04",{"date":324,"type":22},"2036-12-04",{"name":39,"class":40},{"id":327,"slug":328,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":17,"sex":18,"minAge":79,"maxAge":132,"enrollmentInfo":333,"targetDuration":4,"studyType":23,"phases":335,"briefSummary":336,"conditions":337,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":344,"leadSponsor":345,"locationsCount":70},"100552308","developing-strategies-to-facilitate-consent-of-legally-authorized-representatives-to-clinical-trials-100552308","NCT06471400","Developing Strategies to Facilitate Consent of Legally Authorized Representatives to Clinical Trials","Developing Strategies to Facilitate Consent of Legally Authorized Representatives to Clinical Trials - a Prospective, Single-arm, Open-label Exploratory Trial","Inclusion Criteria:\n\n* The study will include LARs of adult patients aged 18 years or older who are admitted to the Freiburg University Medical Center in Germany.\n\nExclusion Criteria:\n\n* LARs who have expressed their unwillingness to participate in the study or have objected to the measures implemented in the study will not be included.",{"count":334,"type":22},50,[25],"This study aims to gather insights into the perceptions of legal representatives regarding the recruitment process for clinical trials in the intensive care setting when the patients cannot decide for themselves. With this information, effective strategies will be developed to increase involvement and the feeling of ownership of LARs of (potential) participants in clinical trials and thus enhance and facilitate patient recruitment for clinical trials. The single-arm study design does not include a choice of comparator, as the focus of this trial is to explore the perceptions of the participants at first hand without comparing different cohorts or strategies.",[338,339],"Critical Illness","Loss of Consciousness","2024-06-18",{"date":342,"type":33},"2024-06-24",{"date":340,"type":33},{"date":238,"type":22},{"name":39,"class":40},{"id":347,"slug":348,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":352,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":354,"minAge":79,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":23,"phases":357,"briefSummary":358,"conditions":359,"keywords":361,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":70},"100541518","image-guided-focal-dose-escalation--primary-pc-treated-with-primary-external-beam-hypofractstereotactic-rt-100541518","NCT06330909","Image-guided Focal Dose Escalation- Primary pc Treated With Primary External Beam Hypofract.Stereotactic rt","Image-guided Focal Dose Escalation in Patients With Primary Prostate Cancer Treated With Primary External Beam Hypofractionated Stereotactic Radiation Therapy (HypoFocal-SBRT) - a Prospective, Multicenter, Randomized Phase III Study","HypoF-SBRT","Inclusion Criteria:\n\n1. Histologically confirmed adenocarcinoma of the prostate (histological confirmation can be based on tissue taken at any time, but a re-biopsy should be considered if the biopsy is more than 12 months old)\n2. Primary localized PCa (cN0 and cM0 in mpMRI and PSMA PET):\n\n   * high- or very high-risk according to NCCN v2.2021 (see 20.3) OR\n   * unfavorable intermediate-risk disease according to NCCN v2.2021 (see 20.3)\n3. Signed, written informed consent for HypoFocal-SBRT study\n4. Age \\> 18 years\n5. Previously conducted PSMA-PET\u002FCT and mpMRI scans or PSMA-PET\u002FMR, fulfilling standard requirements for PCa (see also 6.5)\n6. ECOG Performance score 0 or 1\n7. IPSS Score ≤15\n8. Prostate volume ≤75 ml at RT planning\n\nExclusion Criteria:\n\n1. Evidence of neuroendocrine tumor cells\n2. Prior radiotherapy to the prostate or pelvis\n3. Prior radical prostatectomy\n4. Prior focal therapy approaches to the prostate\n5. Time gap between the beginning of ADT and conduction of mpMRI and PSMA PET scans is \\>1 month\n6. Radiologically suspicious or pathologically confirmed lymph node involvement (cN+) in mpMRI and\u002For PSMA PET\u002FCT\n7. Evidence of metastatic disease (cM+) in mpMRI and\u002For PSMA PET\u002FCT\n8. Evidence of cT4 disease in mpMRI or PSMA PET\u002FCT\n9. PSA \\>30 ng\u002Fml prior to starting ADT\n10. Expected patient survival \\\u003C5 years\n11. Bilateral hip prostheses or any other implants\u002Fhardware that would introduce substantial CT artefacts\n12. Contraindication to undergo a mpMRI scan\n13. Prostate surgery (TURP or HOLEP) with a significant tissue cavity or prostate surgery (TURP or HOLEP) within the last 6 months prior to randomization\n14. Medical conditions likely to make radiotherapy inadvisable e.g. acute inflammatory bowel disease, hemiplegia or paraplegia\n15. Previous malignancy within the last 2 years (except basal cell carcinoma or squamous cell carcinoma of the skin), or if previous malignancy is expected to significantly compromise 5 year survival\n16. Any other contraindication to external beam radiotherapy (EBRT) to the pelvis\n17. In mpMRI and PSMA PET\u002FCT or PSMA PET\u002FMRI scans no visible tumor\n18. Participation in any other interventional clinical trial within the last 30 days before the start of this trial\n19. Simultaneous participation in other interventional trials which could interfere with this trial; simultaneous participation in registry and diagnostic trials is allowed\n20. Patient without legal capacity who is unable to understand the nature, significance and consequences of the trial;\n21. Known or persistent abuse of medication, drugs or alcohol\n22. Patients expected to have severe set up problems\n23. Dose constraints for organs at risk cannot be adhered to","MALE",{"count":356,"type":22},374,[25],"Technical advances in radiotherapy (RT) treatment planning and delivery have substantially changed RT concepts for primary prostate cancer (PCa) by (i) enabling a reduction of treatment time and by (ii) enabling a safe delivery of high RT doses. Several studies proposed a dose-response relationship for patients with primary prostate cancer (PCa) and especially in patients with high-risk features a dose escalation should lead to improved tumor control. In parallel to the improvements in RT techniques, diagnostic imaging techniques like multiparametric magnetic resonance imaging (mpMRI) and positron-emission tomography (PET) evolved and enable an accurate depiction of the intraprostatic tumor mass for the first time. The HypoFocal-SBRT study combines ultra-hypofractionated RT \u002F stereotactic body RT (reduction of treatment time) with a focal RT dose escalation on intraprostatic tumor sides by applying state of the art diagnostic imaging and most modern RT concepts. This novel concept will be compared with moderate hypofractionated RT (MHRT), one option for the curative primary treatment of PCa, which has been proven by several prospective trials and is recommended and carried out worldwide. We suspect an increase in relapse-free survival (RFS) and we will also assess quality of life in order to detect potential changes.",[360],"Prostate Cancer",[360,362,363],"HypoFocal","HypoFocal-SBRT","2024-03-19",{"date":366,"type":33},"2024-03-26",{"date":368,"type":33},"2022-08-18",{"date":370,"type":22},"2030-02",{"name":39,"class":40},{"id":373,"slug":374,"hasResults":11,"nctId":375,"briefTitle":376,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":11,"sex":18,"minAge":79,"maxAge":4,"enrollmentInfo":379,"targetDuration":4,"studyType":23,"phases":380,"briefSummary":381,"conditions":382,"keywords":4,"overallStatus":174,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":4},"100528121","pulsed-field-ablation-to-treat-atrial-fibrillation-with-a-novel-multimodality-generator-100528121","NCT06156644","Pulsed-Field-Ablation to Treat Atrial fiBRillation With a novEl multimodalIty Generator","PFA-Breisgau","Inclusion Criteria:\n\n* new onset atrial fibrillation\n\nExclusion Criteria:\n\n* age \\\u003C18 years\n* previous left atrial ablation\n* lack or withdrawal of written informed consent\n* unable to receive ablation therapy",{"count":334,"type":22},[25],"In this first-in-human clinical trial a novel generator (INTELLAPULSE), designed and built by Stockert, which supports highly flexible PFA protocols as well as RF interventions will be used. For 12 months and follow-up for 12 months, after a 3-months blanking period 50 consecutive paroxysmal AF patients, eligible for catheter ablation, will be enrolled.",[383],"Atrial Fibrillation","2023-12-28",{"date":386,"type":33},"2024-01-03",{"date":388,"type":22},"2025-07-01",{"date":390,"type":22},"2026-12-01",{"name":39,"class":40},{"id":393,"slug":394,"hasResults":11,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":11,"sex":18,"minAge":79,"maxAge":399,"enrollmentInfo":400,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":402,"conditions":403,"keywords":4,"overallStatus":174,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":4},"100528871","breisgau-pheno-heart-study-100528871","NCT06166407","Breisgau Pheno Heart Study","The Breisgau Pheno Heart Study","Inclusion Criteria:\n\n* Emergency coronary angiography and age\\>18 years and STEMI or NSTEMI or \"none of these diseases\"\n\nExclusion Criteria:\n\n* Hemoglobin\\\u003C7,0 g\u002Fdl\n* Platelets \\\u003C50.000\u002Fµl\n* Unable to provide written informed consent\n* Age \\> 80 years\n* hematological neoplasia\n* metastasized cancers\n* acute infection (z.B. Sepsis)\n* Chronic Inflammatory conditions (z.B. inflammatory bowel disease, Rheumatoid arthritis, chronisch hepatitis)\n* Pregnancy\n* Immunosuppression\n* Resuscitation \\>5 min oder mehr als 1x Defibrillation vor Koronarangiographie\n* Cardiogenic shock\n* Mechanical circulatory support\n* Cardiomyopathy with an left ventricular ejection fraction F \\\u003C40% before the event\n* Dialysis\n* Cirrhosis \\> CHILD-A\n* Not living in the county of Breisgau-Hochschwarzwald or Emmendingen oder planned relocation\n* Alcohol and drug abuse\n* Non-compliance","85 Years",{"count":401,"type":22},400,"Coronary heart disease and its acute complication, myocardial infarction (MI), represent the leading causes of death in Europe and the United States. Although novel treatment strategies have helped to improve survival in patients with MI, a large proportion of patients develops heart failure and is at risk of life-threatening arrhythmias. Complications arising after MI constitute a severe burden not only for the patients themselves, but also for health care systems worldwide.\n\nThe likelihood of these complications depends on the area of myocardial tissue lost and the process of myocardial repair and scar tissue formation after MI ('remodeling') which are modified by the local and systemic immune response after MI. The immune response is critical after myocardial infarction. In particular, sustained overactive and prolonged inflammatory reactions lead to accentuated myocardial damage and dysfunction. Important mediators of the inflammatory reaction after MI are monocytes, T-cells, B-cells and hematopoietic stem and progenitor cells. Following MI, myeloid cells derived from the hematopoietic system drive a sharp increase in systemic leukocyte levels that correlates closely with mortality. T- and B-cells in particular act in response to specific antigens. Most of the data regarding the inflammatory response after MI, however, are derived from animal models. The immunological phenotypes after MI and their association with clinical outcome in humans are insufficiently characterized.\n\nAims: The aim of this project is to provide establish clinically and immunologically well-characterized cohort of patients after MI This will aid in identifying novel prognostic cellular and humoral biomarkers that may be used to identify patients at a high inflammatory and immune risk and to guide clinical management. Furthermore, these mediators, in the future, may be targeted by novel antigen-specific immunomodulatory approaches.\n\nPatients with myocardial infarction (STEMI and NSTEMI) will be recruited after PCI within 24h and receive a structured follow-up. Clinical read-outs include a detailed and standardized patient history, clinical examination, standard blood work, coronary angiography, ECG, echocardiography and for subgroups, MRI. Patients will present for study visits at 6 weeks, 3 months and 12 months after the initial event. Blood will be sampled at the inclusion and during follow-up visits. Peripheral blood mononuclear cells and plasma will be stored at the Cardiovascular BioBank (CVBB) and FREEZE, both institutions at the University Hospital in Freiburg. Major adverse cardiac events (myocardial infarction, stroke, hospitalization for heart failure, cardiovascular death) will be recorded using telephone interviews and standardized queries to the local authorities. Several laboratory read-outs are planned including flow cytometry, mass cytometry, single cell RNA sequencing, T cell and B cell receptor sequencing and bulk-RNA-sequencing. In an initial approach we aim to recruit 400 patients with MI, of which we expect ≈40 to develop ischemic cardiomyopathy. Differences in immunological profiles between patients that develop MI and a propensity-matched control group will then be analyzed and correlated with clinical outcome data.",[404,405,406],"Myocardial Infarction","STEMI","NSTEMI","2023-12-12",{"date":409,"type":33},"2023-12-19",{"date":411,"type":22},"2024-04",{"date":413,"type":22},"2034-04",{"name":39,"class":40},{"id":416,"slug":417,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":419,"acronym":4,"eligibilityCriteria":420,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":421,"targetDuration":422,"studyType":53,"phases":4,"briefSummary":423,"conditions":424,"keywords":426,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":70},"100501632","the-university-of-freiburg-medical-center-extracorporeal-organ-support-device-registry-100501632","NCT05811780","The University of Freiburg Medical Center Extracorporeal Organ Support Device Registry","Inclusion Criteria:\n\n* Treatment with any kind of extracorporeal organ support\n\nExclusion Criteria:\n\n* none",{"count":216,"type":22},"10 Years","A prospective registry collecting pseudonymized clinical and treatment data from all patients treated with extracorporeal organ support (i.e., VV ECMO, VA ECMO, ECPR, Impella, IABP, and others) on the wards of the Department of Interdisciplinary Medical Intensive Care at the Freiburg University Medical Center.",[425],"Medical Condition Requiring Extracorporeal Organ Support",[427,428,429,430,166,169],"Acute Respiratory Distress Syndrome","acute respiratory failure","severe respiratory failure","cardiogenic shock","2023-03-31",{"date":433,"type":33},"2023-04-13",{"date":435,"type":33},"2014-04-29",{"date":437,"type":22},"2035-12-31",{"name":39,"class":40},""]